|Bid||0.53 x 1300|
|Ask||0.53 x 1100|
|Day's Range||0.5250 - 0.5615|
|52 Week Range||0.3580 - 2.4600|
|Beta (3Y Monthly)||1.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.60|
Conformis, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants designed to fit each patient’s unique anatomy, today announced preliminary, unaudited, revenue results for the fourth quarter and the year ended December 31, 2018.
BILLERICA, Mass., Dec. 18, 2018 -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop,.
Optimize sales, marketing and administrative expense to take advantage of recently achieved gross margin & operational efficienciesSharpen focus on new product development.
While small-cap stocks, such as Conformis, Inc. (NASDAQ:CFMS) with its market cap of US$32m, are popular for their explosive growth, investors should also be aware of their balance sheet to Read More...
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
ConforMIS (CFMS) delivered earnings and revenue surprises of 40.00% and 50.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Billerica, Massachusetts-based company said it had a loss of 12 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
BILLERICA, Mass., Oct. 31, 2018 -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop,.
ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conformis Inc (NASDAQ:CFMS), a US$58m small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an Read More...
Two important questions to ask before you buy Conformis Inc (NASDAQ:CFMS) is, how it makes money and how it spends its cash. This difference directly flows down to how muchRead More...
The Billerica, Massachusetts-based company said it had a loss of 24 cents per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The idea is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not validate (is not equivalent to) its higher earnings and therefore has room to run justifies investors’ inclination toward low P/E stocks.Source: ©iStock.com/CharlieAJA